The significant side effect of eptifibatide described in the PURSUIT trial was bleeding. In most cases, bleeding was mild and occurred at femoral access sites. More red cell transfusions were required in the eptifibatide group than placebo to counteract anemia.

Thrombocytopenia is another side effect of eptifibatide reported in several case reports.